RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Ferenci, Tamás; Sarkadi, Balázs

doi:10.1186/s12879-022-07069-z

Cited by 29 publications

(20 citation statements)

References 49 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, though these titers appear to increase slightly with age, the difference was not statistically significant, and could be explained by a relatively greater representation of Group III participants in the higher age brackets ( Table 1 ). Lack of correlation of age with antibody titers post-BBIBP CorV has been shown by Petrović et al [ 27 ], and El Ghitany et al [ 35 ] as well, though Ma et al [ 36 ] and Ferenci et al [ 19 ] have reported a negative correlation of post-vaccination immunity and age. Zhang et al also show a small negative correlation with age (r = −0.36), while age was non-significant in the female sub-group of those study participants [ 26 ].…”

Section: Resultsmentioning

confidence: 96%

“…WHO approved a global BBIBP-CorV roll-out in May 2021 [ 18 ]. Although BBIBP-CorV is now approved for use in 90 countries ( Figure S2 ), compared to some other vaccines, there is a paucity of published data reporting neutralizing antibody immune response following BBIBP-CorV in different populations [ 19 ]. We have not come across any published data from Pakistan which elucidates neutralizing antibody response in the population to any of the approved vaccines in the country.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population

et al. 2022

View full text Add to dashboard Cite

Fifty five percent of the Pakistani population is still unvaccinated with the two-dose protocol of COVID-19 vaccines. This study was undertaken to determine the seroconversion rate and antibody titers following the two-dose BBIBP-CorV protocol, and to compare these variables in unvaccinated, COVID-19 recovered individuals (total n = 180) at Indus Hospital and Health Network, Karachi. Pseudotyped lentivirus antibody neutralization assays and SARS-CoV-2 IgG Quant II (Abbott) immunoassays were performed 4-8 weeks following the second dose of the BBIBP-CorV or PCR positivity/onset of symptoms of COVID-19. Seroconversion rate, using neutralization assays, in vaccinated individuals was lower (78%) than that in unvaccinated, COVID-19-recovered individuals with moderate to severe infection (97%). Prior PCR positivity increased serocoversion rate to 98% in vaccinated individuals. Immunoassays did not, however, reveal significant inter-group differences in seroconversion rates (≥95% in all groups). Log10 mean antibody neutralizing titers following the two-dose BBIBP-CorV protocol (IC50 = 2.21) were found to be significantly less than those succeeding moderate to severe COVID-19 (IC50 = 2.94). Prior SARS-CoV-2 positivity significantly increased post-vaccination antibody titers (IC50 = 2.82). Similar inter-group titer differences were obtained using the immunoassay. BBIBP-CorV post-vaccination titers may, thus, be lower than those following natural, moderate to severe infection, while prior SARS-CoV-2 exposure increases these titers to more closely approximate the latter.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Indeed, our result was expected, given that the response to vaccines is generally reduced in older individuals, due to their immune “senescence” ( 21 ), which has been well documented for SARS-CoV-2 Pfizer/BioNTech vaccination ( 22 ). Although Sinopharm vaccines have been widely used in China, Bahrain and the United Arab Emirates, relatively few studies have evaluated antibody titres before and after Sinopharm vaccination, making our findings of significance for a large proportion of the world’s vaccination effort ( 23 – 25 ). Furthermore, in agreement with our findings, these previous studies similarly conclude that SARS-CoV-2 antibody production after Sinopharm vaccination was decreased with increasing age.…”

Section: Discussionmentioning

confidence: 92%

The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine

Farid

Herrera-Uribe²,

Stevenson³

2022

Front. Immunol.

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 emerged in China in 2019 and has since travelled the world infecting millions. SARS-CoV-2 causes Corona Virus Disease (COVID-19), that has to date taken over 4 million lives. The Kingdom of Bahrain’s vaccine roll-out has consisted of Sinopharm’s BBIBP-CorV (Sinopharm) and Pfizer/BioNtech’s BNT162b2 (Pfizer/BioNtech). Testing for SARS-CoV-2 anti-Spike (S) antibodies is a useful technique in estimating an individual’s immune protection against the infection. In this study we evaluated S antibody levels by electro-chemiluminescence immunoassay in 379 individuals double vaccinated with Sinopharm and 15 of whom were given a booster with the Pfizer/BioNtech vaccine. Among our double vaccinated cohort, we found a spectrum of S antibody levels. Indeed, we found that a significant proportion of individuals with low S antibody levels had clinical conditions, which were mainly immune-related disorders. Furthermore, a significant proportion of individuals with low S antibody levels were above 50 years of age. Finally, we observed a significant increase in S antibody levels after the Pfizer/BioNtech booster was administered. These findings reveal that while a large proportion of Sinopharm vaccinated individuals did not develop high levels of antibodies against the S protein, a booster dose of the Pfizer/BioNtech vaccine significantly enhances S antibody levels, revealing this “triple dose” vaccination strategy as a useful method of ensuring protective immunity against SARS-CoV-2.

show abstract

“…Although there are data regarding the duration and persistence of antibody and T cell responses following many COVID‐19 vaccines such as BNT162b2 (Pfizer–BioNTech), AZD1222 and mRNA‐1273 14 , 15 there are limited data regarding the persistence of immune responses following Sinopharm/BBIBP‐CorV. 16 It is crucial that severe disease and hospitalizations due to COVID‐19 are curtailed to a level that it no longer becomes a global threat. While vaccinating all individuals worldwide is essential to end the pandemic, it is also important to monitor the duration of immunity and any changes in vaccine efficacy over time.…”

Section: Introductionmentioning

confidence: 99%

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine

Jeewandara

Aberathna

Pushpakumara

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background To determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP‐CorV, we investigated immune responses in a cohort of Sri Lankan individuals. Methods SARS‐CoV‐2 specific total antibodies were measured in 20–39 years ( n = 61), 40–59 years ( n = 120) and those >60 years of age ( n = 22) by enzyme‐linked immunosorbent assay, 12 weeks after the second dose of the vaccine. Angiotensin‐converting enzyme 2 (ACE2) receptor blocking antibodies (ACE2R‐Ab), antibodies to the receptor‐binding domain (RBD) of the ancestral virus (WT) and variants of concern, were measured in a sub cohort. T cell responses and memory B cell responses were assessed by ELISpot assays. Results A total of 193/203 (95.07%) of individuals had detectable SARS‐CoV‐2 specific total antibodies, while 67/110 (60.9%) had ACE2R‐Ab. A total of 14.3%–16.7% individuals in the 20–39 age groups had detectable antibodies to the RBD of the WT and variants of concern, while the positivity rates of those ≥60 years of age was <10%. A total of 14/49 (28.6%) had Interferon gamma ELISpot responses to overlapping peptides of the spike protein, while memory B cell responses were detected in 9/20 to the S1 recombinant protein. The total antibody levels and ACE2R‐Ab declined from 2 to 12 weeks from the second dose, while ex vivo T cell responses remained unchanged. The decline in ACE2R‐Ab levels was significant among the 40–59 ( p = .0007) and ≥60 ( p = .005) age groups. Conclusions Antibody responses declined in all age groups, especially in those ≥60 years, while T cell responses persisted. The effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies.

show abstract

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Cited by 29 publications

References 49 publications

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population

The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine

Contact Info

Product

Resources

About